Step by Step

INTRODUCTION

ABIM MOC Activity ID

11/5/2019 - Medical Grand Round: Thrombotic Thrombocytopenic Purpura: From empiricism to targeted therapy

QUIZ

EVALUATION

CERTIFICATE

INTRODUCTION

Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Describe the rationale for for using therapeutic plasma exchange and its effectiveness in TTP
  • Describe the mechanism of action of caplacizumab and its role in the current management of TTP.
  • Examine the role of ADAMTS13 in acquired TTP.

Suggested Additional Reading:

  1. Lopez JA, Chen J, Moake JL, Chung DW. Thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. In Consultative Hemostasis and Thrombosis, 3rd Edition, edited by CS Kitchens, CM Kessler, and Konkle BA. Elsevier, Philadelphia, 2013, 423-41.
  2. Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. Journal of clinical apheresis 2019;34(3):171-354.
  3. Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. The New England journal of medicine 2019;380(4):335-46.

Authors:
David Green, MD, PhD — Professor Emeritus of Medicine, Division of Hematology/Oncology Feinberg School of Medicine Northwestern University
No relationships with industry relevant to the content of this educational activity have been disclosed.
Joseph E. Kiss, MD — Professor of Medicine, Division of Hematology/Oncology University of Pittsburgh School of Medicine Medical Director, Clinical Apheresis and Blood Services Vitalant
No relationships with industry relevant to the content of this educational activity have been disclosed.
Authors disclosure of relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients is listed above. No other planners, members of the planning committee, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits. Each physician should only claim credit commensurate with the extent of their participation in the activity.

The University of Pittsburgh is an affirmative action, equal opportunity institution.